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Abstract
Aim: This study aims to evaluate the correlation between oesophageal cancer histopathology and the standardised 
uptake value (SUV) of the primary lesion on positron emission tomography/computed tomography (PET/CT) scan.
Methods: We reviewed clinical data of consecutive newly diagnosed oesophageal cancer patients who underwent 
positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with CT (18F-FDG PET/CT) 
between September 2009 and July 2014.
Results: A total of 289 baseline scans were performed in this 55-month period. Of these, 171 (59%) were male. The 
mean age was 52.6 years (standard deviation ± 12.4 years). On histological review, 214 were squamous cell carcinomas 
(SCCa) and 75 were adenocarcinomas. Of the SCCa, 15.9% were poorly differentiated, 70.6% were moderately 
differentiated and 13.5% were well differentiated. Of the adenocarcinomas, 20% were poorly differentiated, 45% were 
moderately differentiated, 28% were well differentiated and signet ring cell was 7%. Mean maximum SUV (SUVmax) 
for SCCa was 12.6 ± 5.14 and 10.5 ± 6.2 for adenocarcinomas. In bivariate analysis, being a female was associated with 
a higher SUV in the primary lesion by 1.66 units (P = 0.011) compared to males. Adenocarcinomas were associated 
with a lower SUV by 2.14 units (P = 0.004) compared to SCCa. In bivariate analysis, no significant correlation was 
found between the T-stage of the tumour and the SUVmax of the primary tumour (P = 0.339). Multivariate analyses 
showed no association of the SUV of the primary oesophageal tumour with the degree of differentiation of either 
SCCa or adenocarcinoma. There was no correlation between the SUVmax of the primary lesion and the presence or 
activity level of a metastatic focus, whether visceral or nodal.
Conclusion: At our centre, three-fourths of patients with oesophageal carcinoma had squamous cell carcinoma on 
histology. Adenocarcinoma is associated with a lower SUV compared to SCCa. There is no association between the 
SUVmax and degree of differentiation of the primary oesophageal cancer.
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Introduction
Oesophageal cancer is the eighth most common cancer 
worldwide, with nearly 456,000 new cases diagnosed in 
2012 (3% of the total).[1] It is a leading cause of cancer 
mortality amongst men. The incidence ranges from 
2.5 to 5.0 for men and 1.5–2.5 for women per 100,000 
population. It has a relatively poor prognosis with a 5-year 
survival of 6–11%.
Worldwide, squamous cell carcinomas (SCCa) are the 
most common type of cancer of the oesophagus, although 
adenocarcinoma is more prevalent in the west. Similarly, 
in Pakistan, SCCa is the most frequent histology.[2] Various 
factors including smoking, poor oral health, low fresh 
fruit and vegetable intake and the patient’s socioeconomic 
status have been found to influence the histopathological 
type of oesophageal cancer.[3]
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In the 1960s and 1970s, the 5-year survival of patients with 
oesophageal cancer was only about 5%. At present, nearly 
20% of patients survive at least 5 years after the diagnosis 
of oesophageal cancer.[1] In hopes of further improving 
survival, it is important to understand the metabolic 
signature of this cancer and to evaluate the correlation 
between the histology and the level of fluorodeoxyglucose 
(FDG) uptake.
Methods
This study was carried out in the Department of Nuclear 
Medicine at Shaukat Khanum Memorial Cancer Hospital 
and Research Centre (SKMCH and RC), a 189-bed cancer 
specialist centre in Lahore, Pakistan. We reviewed the 
medical records of all gastroesophageal cancer patients 
who were referred to our department for a baseline staging 
positron emission tomography/computed tomography 
(PET/CT) scan using 18F-FDG (18F-FDG) during a 
period of 55 months from September 2009 to July 2014. 
We included in the study all patients who had a proven 
histopathology of primary oesophageal carcinoma. This 
study was approved by the Institutional Review Board at 
SKMCH and RC.
Pathology
All histopathological specimens were reviewed by 
experienced pathologists using standard techniques. 
Immunohistochemical staining was performed when 
appropriate. The pathological stage was assessed using 
the tumour, node and metastasis international staging 
system. Each specimen was classified based on glandular 
formation in adenocarcinoma and keratin pearl formation 
for squamous cell carcinoma and was also categorised 
according to differentiation.
Imaging
Imaging was performed on a dedicated Phillips Gemini 
TOF PET/CT scanner. Patients were asked to fast for 
at least 4 h before the scan and then received a dose 
of 300 MBq (0.21 mCi/kg body weight) of 18F-FDG 
intravenously. Uptake period in a quiet room was 
60 min. Thereafter, images were acquired from the base 
of the skull to the mid-thigh with 3 min acquisition for 
each of 8–9-bed positions. If skeletal metastases were 
found, additional images to include the limbs were 
obtained. A contrast-enhanced CT scan (CECT) with a 
voltage of 70–140 kVp and tube current of 80 mA was 
used for attenuation correction and lesion localisation. 
Dual interpretation of scans was performed by certified 
radiologists and nuclear medicine physicians. Maximum 
standardised uptake value (SUVmax) was determined by 
drawing regions of interest on attenuation corrected FDG 
images around the primary tumour and metastatic lesions.
An iodinated CECT was obtained for attenuation 
correction of PET images as well as for anatomical 
localisation. Iodinated contrast was not used if there was 
a documented history of contrast allergy in the past or 
if serum creatinine was above 1.4 mg/dl. Patients were 
encouraged to void before scanning, and 8 oz of water 
were given to distend the stomach just before imaging.
We evaluated the correlation of SUV with basic patient 
demographics, histopathology and the degree of 
differentiation. In addition, the SUV of the primary tumour 
site was compared to the presence or absence of metastases 




Of the 289 patients, 171 (59%) were male and 118 (41%) 
were female [Table 1]. The mean age was 52.6 years (standard 
deviation [SD] ± 12.4 years). Histopathological review of 
the primary oesophageal tumour showed that 214 (74.5%) 
were SCCa and 75 (25.5%) were adenocarcinomas.
Of the SCCa, 34 (15.9%) were poorly differentiated, 
151 (70.6%) were moderately differentiated and 34 (15.9%) 
were well differentiated. Of the adenocarcinomas, 
15 (21.4%) were poorly differentiated, 34 (48.6%) 








Female 118 (41) 12 (10) 106 (90) 
Male 171 (59) 62 (37) 108 (63) 
JOURNAL OF CANCER & ALLIED SPECIALTIES 3
ORIGINAL ARTICLE J Cancer Allied Spec 2015;1(1):5
The mean SUVmax for SCCa was 12.6 ± 5.14 and 
10.5 ± 6.2 for adenocarcinomas. For SCCa, the mean 
SUVmax on baseline scanning for poorly, moderately 
and well-differentiated carcinomas was 12.5 (SD: 5.6), 
12.6 (SD: 5.1) and 13.4 (SD: 4.1), respectively. For 
adenocarcinomas, the corresponding mean SUVmax 
was 10.3 (SD: 6.2), 11.2 (SD: 5.7) and 9.6 (SD: 6.9), 
respectively.
Based on the T-stage of the primary tumour, 0.3% were 
T1, 0.7% T2, 53.6% T3 and 45.3% T4 tumours [Table 3].
In bivariate analysis, being a female was associated with a 
higher SUV in the primary lesion by 1.66 units (P = 0.011) 
compared to males. Adenocarcinomas were associated 
with a lower SUV by 2.14 units (P = 0.004) compared to 
SCCa. Bivariate analysis showed no significant correlation 
between the T-stage of the tumour and the SUVmax of 
the primary tumour mass (P = 0.339).
In multivariate analyses, SUV of the primary oesophageal 
tumour was not associated with age (P = 0.06), gender 
(P = 0.54) or the degree of differentiation of the primary 
tumour (P = 0.76). In addition, there was no statistically 
significant correlation between the SUVmax of the primary 
lesion and the presence or activity level of a metastatic focus, 
whether visceral or nodal (P = 0.45) [Figures 1 and 2].
Discussion
Although survival from oesophageal cancer is improving, 
it still remains fairly poor. The initial tumour stage 
depends on the depth of tumour invasion, involvement 
of regional lymph nodes and the presence or absence of 
metastatic disease.[4] Accurate pre-treatment workup is 
critical to stage the disease so that undertreatment and/
or unnecessary overtreatment is avoided. Treatment 
strategies should follow guideline recommendations and 
should be developed after multidisciplinary evaluation.
Table 2: Histopathological classification and average SUV of oesophageal carcinoma (n=289)
Type  n (%)  Differentiation  n (%)  Mean SUV+S.D 
Squamous cell carcinoma 214 (74.5%) Well 29 (13.5%) 13.4±4.1 
Moderate 151 (70.6%) 12.6±5.1 
Poor 34 (15.9%) 12.5±6.1 
Adenocarcinoma 75 (25.5%) Well 21 (30%) 9.6±6.9 
Moderate 34 (48.6%) 11.2±5.7 
Poor 15 (21.4%) 10.3±6.2 
Signet ring cell 5 (7%) 4.5±1.8 
SUV: Standardised uptake value, SD: Standard deviation
Table 3: T‑stage distribution (n=289)
T‑stage  n (%) 
T1 1 (0.3) 
T2 2 (0.7) 
T3 155 (53.6) 
T4 131 (45.3) 
Figure 1: 18F-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography images of a 50-year-old 
female with well-differentiated adenocarcinoma of the mid-
oesophagus, showing intense FDG uptake in the primary tumour 
site (standardised uptake value [SUV] of 13) together with 
metastatic mediastinal and hilar nodes. Significantly increased 
uptake is also seen in metastatic pulmonary nodules (SUV of 5.5)
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Several studies have already shown that PET/CT scan is 
superior to oesophageal ultrasound and CT scan in the 
evaluation of metastases at the time of baseline staging. 
The SUVmax has been shown to correlate with tumour 
differentiation in various malignancies including lung 
cancer, head and neck cancer and oesophageal carcinoma. 
One study evaluated 102 pancreatic adenocarcinoma 
patients and found that the SUV was related to the 
histologic grade that it might be a competitive predictor 
for patient survival and that prognosis could be stratified 
according to SUV.[5]
However, for oesophageal cancer, the available evidence 
suggests a mixed picture. Mu et al. found no association 
between SUVmax and the degree of differentiation or 
clinical stage of oesophageal cancer.[6] Similarly, Sun 
et al. studied 112 patients with oesophageal squamous 
cell cancer and found no significant correlation between 
the SUVmax and the clinical stage or the degree of 
tumour differentiation. They also saw no significant 
difference in patients’ gender, age or N and M stage in 
relation to the SUVmax after controlling for tumour 
length.[7] However, a meta-analysis by Pan et al. 
comprehensively reviewed the available literature and 
concluded that the SUV in oesophageal cancer patients 
can serve as a prognostic indicator.[8,9] Similarly, Feng 
et al. studied 68 patients with oesophageal cancer and 
found a statistically significant difference in SUVmax 
between the poorly differentiated group and the 
moderately or well-differentiated group (r = 0.781, 
P = 0.000). They also found a statistically significant 
increase in the SUVmax of oesophageal lesions with 
nodal metastases compared to those without.[8] The 
sample size was, however, relatively small, and may 
have affected the quality of the data.
Our study showed a statistically significant correlation 
between the histology and the SUV of the primary lesion. 
Further, analysis showed no statistically significant 
difference in the SUV based on the degree of differentiation 
of either adenocarcinoma or SCCa. We also saw no 
correlation between the SUV of the primary tumour 
and the presence or the degree of uptake in metastatic 
lesions, whether nodal or visceral. In terms of tumour 
histopathology, we found that 74% of our sample had 
squamous cell carcinoma while 25% had adenocarcinoma. 
This finding is in marked contrast to the data reported 
from the western hemisphere, where, over the past 4 
decades, there has been a rising incidence of oesophageal 
adenocarcinoma. In the US, according to the National 
Cancer Institute’s Surveillance, Epidemiology and End 
Result programme, compared to 1974–1975, there was 
a >350% increase in annual rate of adenocarcinoma 
by 1992–1994.[10] Adenocarcinoma in the early 1980s 
accounted for <15% of all oesophageal cancers, and 
by the 1990s, it represented >60% of all oesophageal 
carcinomas.[11] In contrast, Ali et al. have reported data 
on 69 patients in the northern areas of Pakistan and 
found that 92.5% of cases of oesophageal malignancy 
were squamous cell carcinoma, while only 5% were 
adenocarcinoma.[12] More work is needed to understand 
these histopathological variations.
Limitations
Data were gathered in a retrospective fashion. At our 
institution, the acceptance criteria for the treatment of 
oesophageal cancer patients limit open acceptance of 
all patients. Patients with metastatic pulmonary lesions 
visible on chest X-ray at presentation are not accepted 
for further management at our hospital and are referred 
to outside hospitals.
Figure 2: 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography images of a 36-year-old 
male with well-differentiated squamous cell carcinoma showing 
intense FDG uptake in the mid to distal oesophagus (standardised 
uptake value [SUV] SUV of 12.3). Increased uptake is also seen 
in regional nodes as well as in a metastatic left supraclavicular 
lymph node (SUV of 8)
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Conclusion
At our centre, three-fourths of patients with oesophageal 
carcinoma presented with squamous cell carcinoma. 
Adenocarcinoma is associated with a lower SUV 
compared to SCCa. There is no association between the 
SUVmax and degree of differentiation of the primary 
oesophageal cancer.
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